One glass of white wine ups risk of developing skin cancer
Drinking a small glass of white wine per day could increase the risk of skin cancer by 13%, and by 73% if a glass and a half is drunk daily, according to a study by Professor Eunyoung Cho at Brown University. The research warns that drinking alcohol is associated with higher rates of invasive melanoma, with white wine carrying the highest risk. Red wine, beer and spirits do not significantly affect melanoma risk as they do not contain the same levels of acetaldehyde. About 2,500 people in the UK die from malignant melanoma annually, and around 3.6% of cancer cases globally are attributed to alcohol.

Bottom Line: Alcohol intake was associated with higher rates of invasive melanoma among white men and women. White wine carried the most significant association, and the increased risk was greater for parts of the body that receive less sun exposure.

Journal in Which the Study was Published: Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

Author: Eunyoung Cho, ScD, an associate professor of dermatology and epidemiology at the Warren Alpert Medical School of Brown University in Providence, Rhode Island.

Background: Approximately 3.6 percent of cancer cases worldwide have been attributed to alcohol, most typically cancers of the aerodigestive tract, liver, pancreas, colon, rectum, and breast. Previous research has suggested that alcohol can cause carcinogenesis as the ethanol in alcohol metabolizes into acetaldehyde, which damages DNA and prevents DNA repair.

How the Study Was Conducted: Cho and colleagues sought to determine whether alcohol consumption increased melanoma risk. They used data from three large prospective cohort studies in which 210,252 participants were followed for a mean of 18.3 years, using food-frequency questionnaires to determine their alcohol consumption. A standard drink was defined as 12.8 grams of alcohol.

Results: Overall alcohol intake was associated with a 14 percent higher risk of melanoma per drink per day. Each drink per day of white wine was associated with a 13 percent increased risk of melanoma. Other forms of alcohol--beer, red wine, and liquor--did not significantly affect melanoma risk.

The association between alcohol and melanoma was strongest for parts of the body that typically receive less sun exposure. Cho said that compared with nondrinkers, those who consumed 20 grams or more of alcohol per day were 2 percent more likely to be diagnosed with melanomas of the head, neck, or extremities, but 73 percent more likely to be diagnosed with melanomas of the trunk. She said this finding was novel and further research would be required to explain the results.

Author Comment: Cho said it was surprising that white wine was the only drink independently associated with increased risk of melanoma. The reason for the association is unknown. However, research has shown that some wine has somewhat higher levels of pre-existing acetaldehyde than beer or spirits. While red and white wine may have similar amounts of pre-existing acetaldehyde, the antioxidants in red wine may offset the risks, Cho said.

Cho said the study adds melanoma to the list of cancers associated with alcohol, and the findings support existing recommendations by organizations including the American Cancer Society to limit alcohol intake.

"The clinical and biological significance of these findings remains to be determined, but for motivated individuals with other strong risk factors for melanoma, counseling regarding alcohol use may be an appropriate risk-reduction strategy to reduce risks of melanoma as well as other cancers," Cho said.

However, Cho pointed out that modest alcohol intake has been connected with reduced risk of cardiovascular disease.

"For drinkers, risks and benefits of alcohol consumption have to be considered individually, including the risk related to skin cancer," she said.

Limitations: Cho said the study's chief limitation was the homogeneity of the study population. Non-whites were excluded, as there were too few non-white participants to draw statistically valid conclusions. Therefore, the study's findings cannot be generalized for other racial or ethnic groups.

Also, few study participants reported heavy drinking, and the study did not account for some potential risk factors of melanoma, such as sun-protection behaviors. Participants were excluded if they reported a personal history of cancer at baseline of the follow-up in order to avoid bias due to closer physician follow-up of cancer patients.

###

Funding & Disclosures: This study was supported by grants from the National Institutes of Health. Cho declares no conflicts of interest.

Follow us: Cancer Research Catalyst http://blog.aacr.org; Twitter @AACR; and Facebook http://www.facebook.com/aacr.org

For AACR information, visit Fast Facts

About the American Association for Cancer Research

Founded in 1907, the American Association for Cancer Research (AACR) is the world's first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 37,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 108 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops, the largest of which is the AACR Annual Meeting with nearly 19,500 attendees. In addition, the AACR publishes eight prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit http://www.AACR.org.

To interview Eunyoung Cho, please contact Julia Gunther at julia.gunther@aacr.org or 215-446-6896.